Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

400 Press Releases
DateTitleCompany
27 Jan 16 Idiopathic Pulmonary Fibrosis (IPF): OFEV?® (nintedanib) is recommended for use within the NHS by the National Institute for Health and Care Excellence (NICE) Boehringer Ingelheim,
Published by
Business Wire
17 Jan 16 Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®▼ (empagliflozin) as an option for patients with type 2 diabetes in Wales Boehringer Ingelheim ,
Published by
PharmiWeb.com
12 Jan 16 Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®? (empagliflozin) as an option for patients with type 2 diabetes in Wales Boehringer Ingelheim,
Published by
Business Wire
21 Dec 15 Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer Boehringer Ingelheim,
Published by
Business Wire
18 Dec 15 Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress Boehringer Ingelheim ,
Published by
PharmiWeb.com
09 Dec 15 New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Dec 15 Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Dec 15 Boehringer Ingelheim (Canada) Ltd.'s Targeted Lung Cancer Therapy, GIOTRIF® (afatinib), Recognized with Prestigious Prix Galien Canada - Innovative Product Award Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Dec 15 Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment Boehringer Ingelheim ,
Published by
PharmiWeb.com
30 Nov 15 Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
PharmiWeb.com
30 Nov 15 Health Canada approves JARDIANCE™ (empagliflozin) tablets for adults with type 2 diabetes Boehringer Ingelheim (Canada) Ltd.,
Published by
PR Newswire
30 Nov 15 Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment Boehringer Ingelheim,
Published by
Business Wire
26 Nov 15 Praxbind® ? (idarucizumab) licensed in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
23 Nov 15 FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery Boehringer Ingelheim,
Published by
PharmiWeb.com
18 Nov 15 Boehringer Ingelheim Makes Twitter #COUGH for World COPD Day Boehringer Ingelheim,
Published by
Business Wire
17 Nov 15 NICE Endorsed Tool Launched to Support Patients and Doctors in Shared Decision-Making. Boehringer Ingelheim,
Published by
Business Wire
16 Nov 15 Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Nov 15 Boehringer Ingelheim Presents New Praxbind® (idarucizumab) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran Boehringer Ingelheim,
Published by
PharmiWeb.com
02 Nov 15 Boehringer Ingelheim Recognized on Science Magazine's 2015 Top Employer List Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
22 Oct 15 New Results From a Patient Registry Reveal Insights About Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
16 Nov 15 Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care Boehringer Ingelheim,
Published by
PharmiWeb.com
28 Oct 15 New Results From a Patient Registry Reveal Insights About Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Oct 15 New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
02 Nov 15 Boehringer Ingelheim and BioMed X Extend Collaboration to Discover Novel Therapeutic Concepts for the Treatment of Psychiatric Diseases Boehringer Ingelheim ,
Published by
PharmiWeb.com
02 Nov 15 Boehringer Ingelheim Recognized on Science Magazine's 2015 Top Employer List Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Oct 15 New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Oct 15 New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
Business Wire
30 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
30 Oct 15 Boehringer Ingelheim Release CHEST: New Sub-Analyses Show Improvement In COPD Patient Outcomes With Spiolto Respimat Boehringer Ingelheim ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.